Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Hodgkin Disease 1Hematologic Neoplasms 1Gliosarcoma 1Glioblastoma 1

Interventions

romidepsin 12Cyclophosphamide 10fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Gemcitabine 7Bortezomib 7fludarabine 6Lenalidomide 6Filgrastim 6tanespimycin 5Vorinostat 5Magnetic Resonance Spectroscopy 5Etoposide 5Biopsy 5belinostat 4Tacrolimus 4Depsipeptides 4Brentuximab Vedotin 4Whole-Body Irradiation 3Specimen Handling 3Radiotherapy 3Oxaliplatin 3Nivolumab 3Methylprednisolone 3Lactones 3Irinotecan 3Ipilimumab 3Doxorubicin 3Dexamethasone 3Dasatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, T-Cell, Cutaneous × tinostamustine × Clear all
NCT02576496 2024-07-25

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Mundipharma Research Limited

Phase 1 Completed
106 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Multiple Myeloma, Lymphoma, T-Cell, Cutaneous, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡